



सत्यमेव जयते
Govt. of India

Special Call for Proposals on Pandemic Influenza Vaccine Development

Under
Biotechnology Industry Partnership Programme (BIPP)
(An Advanced Technology Scheme)



About BIPP

Department of Biotechnology (DBT) invites proposals from Indian Biotechnology Companies under the **Biotechnology Industry Partnership Programme (BIPP)**, a Government partnership with industry for support on a cost sharing basis for development of novel and high risk futuristic technologies mainly for viability gap funding and enhancing existing R&D capacities. BIPP has been initiated under Biotechnology Industry Research Assistance Programme (BIRAP), a unique initiative of DBT being implemented in partnership with ABLE and BCIL to nurture R&D and innovation in Biotech Industry. Biotech Consortium India Limited (BCIL) is the BIPP Management Agency and will ensure maintenance of strict confidentiality of the proposals as per DBT norms.

Key Features of the Programme

> Supports:

- Large, medium, small scale industry, start ups on cost sharing basis.
- High risk, discovery linked innovation.
- Accelerated technology development.
- Evaluation and validation of biotech products.
- Indigenous discovery, innovation and technology to products.
- Products of national relevance or public benefit.

> Varying models of grants, loans or grant + loan available.

Eligible Categories

Category I	Areas in healthcare, agriculture, energy and environment with major social relevance but uncertain market driven demand.
Category II	High risk, discovery innovation research including in the area of Biosimilars, with relevance for making India globally competitive.
Category III	Evaluation & Validation of already developed products of high National Importance promoting local innovation.
Category IV	Shared cost for major infrastructure facilities around technology platforms, critical for enabling innovation.

Under this Special Call

The Department of Biotechnology invites R&D proposals aimed towards obtaining safe and efficacious vaccines against pandemic influenza, encompassing relevant areas like novel adjuvants, *in vitro* assays for measuring vaccine elicited immune responses, novel vaccine formulations, delivery technologies and facilitating clinical development process consistent with highest ethical and regulatory standards practiced globally. The accelerated grant award is expected to be highly competitive and technology intensive.

The Call is designed to support:

- > Development of novel improved immunogens or candidate vaccines against pandemic influenza and influenza.
- > Novel adjuvant design and delivery systems to achieve desired level of protective immune responses in the host.
- > Different stages of vaccine research/development:
 - Pre-clinical research (vaccine optimization studies, immunogenicity/challenge studies etc.)
 - GLP/GMP vaccine production
 - Pre-clinical toxicology and safety studies
 - Pre-IND/IND preparation & submission and clinical testing

Who can apply?

- > A single or consortia of Indian "for profit" company (ies) - Small, Medium or Large having DSIR recognised in-house R&D unit(s). An Indian Company is defined as one in which more than 51% of the ownership is by Indian citizens. (including NRIs). The proposals can be submitted:
 - solely by an Indian Company; or
 - jointly by an Indian Company and national R&D organizations and Institutions; or
 - by a group of Indian Companies along with national research organizations etc.

How to apply?

The Companies should submit a detailed proposal strictly in the prescribed format available at DBT website: <http://dbtindia.nic.in/AboutBIPP> as hard copies (6 copies: 1 original + 5 copies) and a soft copy in CD (MS Word file-2003-2007 compatible mode, pdf version will not be accepted) to the following address,

The Managing Director
Biotech Consortium India Limited, 5th Floor
Anuvrat Bhawan, 210 Deen Dayal Upadhyaya Marg
New Delhi - 110002
Tel: +91 11 23219064-67; Fax: +91 11 23219063
E-mail: ceo.bcil@nic.in

Proposals submitted under this call should have clear superscription
"Special Call for Influenza Vaccine Development"

on the cover page of the proposal as well as on the envelope.

Proposals submitted by 31st August 2009 can be processed by 15th October 2009

For Details Contact: **Dr. Renu Swarup**, Advisor Incharge-BIPP / **Dr. S. Sinha**, Advisor, Department of Biotechnology, Block No: 2, 7th Floor, CGO Complex, Lodi Road, New Delhi – 110 003, India. E-mail: swarup@dbt.nic.in / ssinha.dbt@nic.in

Detailed guidelines for the scheme including eligible project categories to be supported are available at

<http://dbtindia.nic.in/AboutBIPP>